|
|
TOV-21G
|
|
|
University of Montreal
|
|
Biosafety Level:
|
1
|
|
|
frozen
|
|
|
See Propagation
|
|
|
adherent
|
|
|
Homo sapiens deposited as human
|
|
|
epithelial
|
|
|
Organ: ovary
Tumor Stage: grade 3, stage III
Disease: primary malignant adenocarcinoma; clear cell carcinoma
|
|
|
keratin
|
|
|
In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
|
|
|
Like OV-90 (ATCC CRL-11732 ), the OV-21G (ATCC CRL-11730 ) cell line exhibits a deletion at chromosome 3p24. The TOV-112D (ATCC CRL-11731 ) cell line does not exhibit a deletion at chromosome 3p24.
|
|
|
Yes
|
|
|
p53 + (wild type)
|
|
|
Amelogenin: X
CSF1PO: 13,15
D13S317: 11,12
D16S539: 10,12
D5S818: 12,13
D7S820: 12
THO1: 7,9.3
TPOX: 8,11
vWA: 17
|
|
|
47, XX, +10 [49408 ]
|
|
|
62 years
|
|
|
female
|
|
|
ATCC complete growth medium: The base medium for this cell line is a 1:1 mixture of MCDB 105 medium containing a final concentration of 1.5 g/L sodium bicarbonate and Medium 199 containing a final concentration of 2.2 g/L sodium bicarbonate. To make the complete growth medium, add the following components to the base medium:
fetal bovine serum to a final concentration of 15%
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Temperature: 37.0°C
|
|
|
Protocol:
-
Remove and discard culture medium.
-
Briefly rinse the cell layer with 0.05% (w/v) Trypsin - 0.53 mM EDTA solution to remove all traces of serum that contains trypsin inhibitor.
-
Add 2.0 to 3.0 ml of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).
Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37?C to facilitate dispersal.
-
Add 6.0 to 8.0 ml of complete growth medium and aspirate cells by gently pipetting.
-
Add appropriate aliquots of the cell suspension to new culture vessels.
-
Incubate cultures at 37?C.
Subcultivation Ratio: A subcultivation ratio of 1:3 to 1:4 is recommended
Medium Renewal: Every 3 to 4 days
|
|
|
Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO
Storage temperature: liquid nitrogen vapor phase
|
|
|
recommended serum:ATCC 30-2020
|
|
|
42090: Mes-Masson AM, Provencher D. Primary cultures of normal and tumoral human ovarian epithelium. US Patent 5,710,038 dated Jan 20 1998
49408: Provencher DM, et al. Characterization of four novel epithelial cancer cell lines. In Vitro Cell. Dev. Biol. Anim. 36: 357-361, 2000. PubMed: 10949993
|
CoC1
|
人卵巢癌細(xì)胞系
|
Lec1
|
倉鼠卵巢細(xì)胞
|
|
A2780
|
人卵巢癌細(xì)胞
|
OVAC
|
卵巢癌細(xì)胞
|
|
Anglne
|
人卵巢癌細(xì)胞系
|
NIH:OVCAR-3
|
人卵巢癌細(xì)胞
|
|
Caov－3
|
人乳突狀卵巢腺癌細(xì)胞
|
PA-1
|
人卵巢畸胎瘤細(xì)胞
|
|
CHO
|
中國倉鼠卵巢細(xì)胞
|
Pr-HNV8
|
菜青蟲卵巢細(xì)胞
|
|
CHO/dhFr-
|
倉鼠卵巢細(xì)胞,二氫葉酸還原酶缺陷
|
RP70-a-CHO-0.8MTX
|
中國倉鼠卵巢細(xì)胞
|
|
CHO-K1
|
中國倉鼠卵巢細(xì)胞
|
SF9
|
晚秋粒蟲卵巢細(xì)胞
|
|
CHO-pt
|
轉(zhuǎn)血小板基因倉鼠卵巢細(xì)胞
|
SKOV3
|
人卵巢癌細(xì)胞
|
|
CHO-S
|
中國倉鼠卵巢懸浮細(xì)胞
|
SKOV-3/DDP
|
卵巢癌順鉑耐藥株
|
|
CoC1
|
人卵巢癌細(xì)胞系
|
SW1910
|
人卵巢癌細(xì)胞
|
|
CoC2
|
卵巢癌
|
SW626
|
人卵巢腺癌細(xì)胞
|
|
CTLA4 Ig-24
|
中國倉鼠卵巢細(xì)胞
|
TOV-21G
|
人卵巢癌
|
|
ES-2
|
人卵巢透明細(xì)胞癌
|
ZA1
|
轉(zhuǎn)S9基因倉鼠卵巢細(xì)胞
|
|
HO-8910
|
人卵巢癌細(xì)胞
|
ZA6
|
轉(zhuǎn)S9基因倉鼠卵巢細(xì)胞
|
|
HO-8910PM
|
人高轉(zhuǎn)移卵巢癌細(xì)胞
|
Cho-K1
|
倉鼠卵巢細(xì)胞亞株
|
|
HOC1
|
卵巢癌細(xì)胞
|
SK-OV-3
|
人卵巢癌細(xì)胞
|
|
Lec1
|
倉鼠卵巢細(xì)胞
|
Sf9
|
昆蟲卵巢細(xì)胞
|
|
CHO-K1
|
倉鼠卵巢細(xì)胞亞株
|
ES-2
|
人卵巢透明細(xì)胞癌
|
|
CHO/dhFr-
|
倉鼠卵巢細(xì)胞,二氫葉酸還原酶缺陷
|
SK-OV-3
|
人卵巢癌細(xì)胞TOV-21G 人卵巢癌細(xì)胞TOV-21G 人卵巢癌細(xì)胞
|
|
